Effect of Biliary Stenting Combined With Ursodeoxycholic Acid Treatment on Retained Common Bile Duct Stones in Elderly Patients
Not Applicable
Recruiting
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0004257
- Lead Sponsor
- Kangbuk Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients who had common bile duct stones that can not be removed by conventional endoscopic techniques, with signs and symptoms of cholangitis such as biliary pain, jaundice, and fever
Exclusion Criteria
1) refuse to participate in the study,
2) If the remaining life expectancy is less than 6 months,
3) Patients who had previously experienced side effects on Ursa medication
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of both the transverse and longitudinal diameters of the common bile duct stones and common bile duct diameter at 6 months after the initial endoscopic retrograde cholangiopanreatography;The rate of complete CBD stones removal at 6 months after the initial endoscopic retrograde cholangiopanreatography
- Secondary Outcome Measures
Name Time Method The rate of immediate or late complications related to biliary stent placement or endoscopic stone removal;The rate of immediate or late complications related to biliary stent placement or endoscopic stone removal;The occurrence of significant adverse side effects from the administration of Ursodeoxycholic acid